PATINA
Clinical Trial Program
A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy after Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer
Phase III
Status
Recruiting
Tumour subtype:
HER2+ breast cancer, HR+ breast cancer
Scenario
Locally Advanced or Metastatic
SPONSOR
PRINCIPAL INVESTIGATORS
Otto Metzger, MD (Dana-Farber Cancer Institute)
Sites
CENTRO ONCOLOGICO MD ANDERSON INTERNACIONAL ESPAÑA, COMPLEJO HOSPITALARIO DE NAVARRA, HOSPITAL CLINIC DE BARCELONA, HOSPITAL CLÍNICO UNIV. SANTIAGO DE COMPOSTELA, HOSPITAL CLÍNICO UNIVERSITARIO DE VALENCIA, HOSPITAL DE FUENLABRADA, HOSPITAL FUNDACIÓN JIMÉNEZ DÍAZ, HOSPITAL QUIRONSALUD SAGRADO CORAZON, HOSPITAL SEVERO OCHOA DE LEGANÉS, HOSPITAL UNIVERSITARI GENERAL DE CATALUNYA, HOSPITAL UNIVERSITARI SANT JOAN DE REUS, HOSPITAL UNIVERSITARI VALL D’HEBRON, HOSPITAL UNIVERSITARIO 12 DE OCTUBRE, HOSPITAL UNIVERSITARIO DE LA PAZ, HOSPITAL UNIVERSITARIO DE SALAMANCA, HOSPITAL UNIVERSITARIO FUNDACIÓN DE ALCORCÓN, HOSPITAL UNIVERSITARIO REGIONAL DE MALAGA, HOSPITAL UNIVERSITARIO VIRGEN DE LA ARRIXACA, HOSPITAL UNIVERSITARIO VIRGEN DEL ROCIO, ICO HOSPITALET (DURAN I REYNALS), CENTRO CLÍNICO FUNDAÇAO CHAMPALIMAUD, HOSPITAL BEATRIZ ANGELO, HOSPITAL DA LUZ, IPO PORTO (INSTITUTO PORTUGUÊS DE ONCOLOGIA DE PORTO FRANCISCO GENTIL, EPE )
